European Pharmaceutical Review
APRIL 26, 2024
“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceutical company Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ).
European Pharmaceutical Review
DECEMBER 12, 2023
The first stage of construction has officially begun on Lek Pharmaceuticals’ new biologics and biosimilars production centre in Lendava, north eastern Slovenia. Sandoz is the parent company of Lek Pharmaceuticals , the oldest pharmaceutical company in Slovenia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 9, 2022
Pharmaceutical Technology Excellence Rankings – The Verdict. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. The company is ranked in the M&A, PRODUCT LAUNCHES and RESEARCH AND DEVELOPMENT categories in the 2022 Pharmaceutical Technology Excellence Rankings.
pharmaphorum
JULY 22, 2021
This really tested pharmaceutical companies,” explains Ki-Sung. We leveraged our ample experience in conducting global clinical trials in the field of monoclonal antibody biosimilar and designed the clinical trial for CT-P59 according to its mechanism of action of a monoclonal antibody to treat COVID-19 patients in early stages.”.
PharmaShots
JUNE 7, 2023
Our team at PharmaShots has summarized 16 key events of the biosimilar space of May 2023 1. based on change from baseline on a standardized DAS28-CRP which evaluates the severity of RA using clinical and laboratory data Additionally, the company initiates PK study for AVT05 in Jan 2023. 84% vs 64%) & 2yr. (60%
Pharmaceutical Technology
MAY 23, 2023
The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. While a handful of incentives are offered by the reform package, they are overshadowed by the potential drawbacks for the innovative sector.
PharmaShots
FEBRUARY 27, 2023
The speakers shared their views on the topic: Dr. Jagadeesh Babu Rangisetty- “COVID has taught us so many things and the pharmaceutical company has gone through a lot of challenges and at the same time opportunities. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.
Expert insights. Personalized for you.
79 
Let's personalize your content